aTYR PHARMA (ATYR) Revenue (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly Revenue came in at $190000.0 in Q3 2025, down 19.15% on a QoQ basis from $235000.0 in Q1 2024.

aTYR PHARMA (ATYR) Revenue (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of Revenue data on file, last reported at $190000.0 in Q3 2025.

Quarterly Revenue changed N/A year-over-year to $190000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $190000.0 (changed N/A YoY) and the FY2025 annual result came in at $190000.0, down 19.15% from the prior year.
Revenue slipped to $190000.0 in Q3 2025, from $235000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $10.4 million in Q4 2022 to a low of $190000.0 in Q3 2025.
A 4-year average of $2.8 million and a median of $294000.0 in 2023 frame the typical range for Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data